XRTX - Xortx stock soars 40% as kidney disease drug shows promise in bridging study

• Xortx Therapeutics ( NASDAQ: XRTX ) said its proprietary formulation of oxypurinol showed a substantial increase in oral bioavailability provided with food compared to the fasted state in a pharmacokinetics bridging study, dubbed XRX-OXY-101, Part 2.
• The company added that the trial also showed a clean safety and pharmacologic profile with no drug related adverse or serious adverse events related to oral administration of oxypurinol.
• XRX-OXY-101 bridging pharmacokinetic study is designed with four important objectives, the company noted in an Aug. 22 press release.
• "Successful completion of Part 1 and now part 2 of the XRX-OXY-101 study provides key data and knowledge for selecting the clinical dose and formulation for future oral dosing for our planned phase 3 registration trial in ADPKD," said Xortx CEO Allen Davidoff.
• The company's planned phase 3 trial in autosomal dominant polycystic kidney disease (ADPKD) expects to begin patient dosing in H1 2023.
• XRTX +40.40% to $2.12 premarket Aug. 22

For further details see: